Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $38.15M | $30.68M | $30.42M | $30.55M |
| Net Income | $6.53M | -$7.71M | $9.44M | $10.09M |
| EPS Diluted | $0.45 |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.54 |
| $0.67 |
| $0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
